Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Rheumatology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3899/jrheum.120725PMID 23378460
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of C‐reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group

  2012cited by this paper
• Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis

  2012cited by this paper
• Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy

  2012cited by this paper
• Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ?

  2011cited by this paper
• Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres

  2011cited by this paper
• STAT3 in tissue fibrosis: is there a role in the lung?

  2011cited by this paper
• Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis

  2011cited by this paper
• Attenuated lung fibrosis in interleukin 6 knock-out mice after C-ion irradiation to lung.

  2011cited by this paper
• Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.

  2010cited by this paper
• B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

  2010cited by this paper
• Increased epithelial permeability in pulmonary fibrosis in relation to disease progression

  2010cited by this paper
• Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma

  2009cited by this paper
• Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.

  2009cited by this paper
• Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension

  2009cited by this paper
• Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis

  2009cited by this paper
• Interstitial lung disease in systemic sclerosis: a simple staging system.

  2008influential reference
• Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.

  2007cited by this paper
• T(H)-17 differentiation: of mice and men.

  2007cited by this paper
• Changes in causes of death in systemic sclerosis, 1972–2002

  2007cited by this paper
• Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis.

  2006cited by this paper
• Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis

  2005cited by this paper
• Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.

  2004cited by this paper
• Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement

  2004cited by this paper
• CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

  2004cited by this paper
• Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts

  2004cited by this paper
• Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

  2003cited by this paper
• American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias

  2002cited by this paper
• Using Aalen's Linear Hazards Model to Investigate Time-varying Effects in the Proportional Hazards Regression Model

  2002cited by this paper
• Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

  2002cited by this paper
• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors

  2002cited by this paper
• Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts.

  2001cited by this paper
• Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

  2001cited by this paper
• Lineage commitment in the immune system: the T helper lymphocyte grows up.

  2000cited by this paper
• Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement

  2000cited by this paper
• Elevated Serum KL-6 Levels in Patients with Systemic Sclerosis: Association with the Severity of Pulmonary Fibrosis

  2000cited by this paper
• Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.

  2000cited by this paper
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

  2000cited by this paper
• Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit.

  1999cited by this paper
• Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.

  1998cited by this paper
• Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.

  1994cited by this paper
• Severe restrictive lung disease in systemic sclerosis.

  1994cited by this paper
• IL‐6 induces hepatic inflammation and collagen synthesis in vivo

  1994cited by this paper
• In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease.

  1993cited by this paper
• Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern.

  1993cited by this paper
• Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

  1991cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper
• American

  1898cited by this paper

• Associations with, and predictors of, progression in systemic sclerosis-related interstitial lung disease: a scoping literature review

  2026cites this paper
• Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood

  2026cites this paper
• Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment

  2026cites this paper
• Immunopathogenic Mechanisms in Connective Tissue Disease-Associated Interstitial Lung Disease: Incessant Loop of Immunity to Fibrosis

  2025cites this paper
• Pilot study of 18F-FAPI-RGD PET/CT for the diagnosis of connective tissue disease associated interstitial lung disease

  2025cites this paper
• Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease

  2025cites this paper
• Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice.

  2025cites this paper
• INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: ASSESSMENT OF POTENTIAL RISK FACTORS AND ASSOCIATION WITH CLINICAL AND INSTRUMENTAL MANIFESTATIONS

  2025cites this paper
• High Ferritin Predicts Mortality in Patients With Interstitial Pneumonia and an Underlying Autoimmune Disease

  2025cites this paper
• Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis

  2025cites this paper
• Cognitive impairment in Sjogren’s syndrome: Interplay between BACE1 activity, inflammatory blood biomarkers and neurocognitive testing

  2025cites this paper
• B cells and systemic sclerosis interstitial lung disease.

  2025cites this paper
• Systemic Sclerosis with Interstitial Lung Disease: Identification of Novel Immunogenetic Markers and Ethnic Specificity in Kazakh Patients

  2025cites this paper
• Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention

  2024cites this paper
• Cytokine correlations in childhood-onset rheumatic diseases with pulmonary involvement

  2024cites this paper
• Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil.

  2024cites this paper
• Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

  2024cites this paper
• Transcriptomic analyses of lung tissues reveal key genes associated with progression of systemic sclerosis-interstitial lung disease (SSc-ILD).

  2024cites this paper
• High Interleukin-13 level is associated with disease stability in interstitial Lung disease

  2024cites this paper
• Pathogenesis and Therapy of Hermansky–Pudlak Syndrome (HPS)-Associated Pulmonary Fibrosis

  2024cites this paper
• Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.

  2024cites this paper
• Fibrosis mechanisms in systemic sclerosis and new potential therapies.

  2024cites this paper
• Pathogenesis of interstitial lung disease in systemic sclerosis

  2024cites this paper
• Systemic sclerosis and interstitial lung disease: From pathogenesis, to screening, diagnosis, and classification

  2023cites this paper
• Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers

  2023cites this paper
• Walking the path of treatable traits in interstitial lung diseases

  2023cites this paper
• Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti–topoisomerase I antibody

  2023cites this paper
• Treatable Traits in Systemic Sclerosis

  2023cites this paper
• Dysregulated B cell function and disease pathogenesis in systemic sclerosis

  2023cites this paper
• Serum interleukin-6 level and its association with pulmonary involvement in progressive systemic sclerosis; a case-control study

  2023cites this paper
• Biomarkers of cellular senescence in idiopathic pulmonary fibrosis

  2023cites this paper
• Pharmacological management of systemic sclerosis associated interstitial lung disease

  2023cites this paper
• Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort

  2023influential citation
• Comprehensive biomarker analysis of patients with idiopathic pulmonary fibrosis and interstitial lung disease with healthy individuals.

  2023cites this paper
• Systemic sclerosis-associated interstitial lung disease: Diagnostic approaches and challenges

  2023cites this paper
• The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis–Associated Interstitial Lung Disease

  2023cites this paper
• State-of-the-art evidence in the treatment of systemic sclerosis

  2023cites this paper
• CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3

  2023influential citation
• Biomarkers of interstitial lung disease in systemic scleroderma and their significance

  2023cites this paper
• Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease

  2023cites this paper
• Serum C‐reactive protein is associated with earlier mortality across different interstitial lung diseases

  2023cites this paper
• Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review

  2023cites this paper
• Recent advances in the treatment of systemic sclerosis associated interstitial lung disease

  2023cites this paper
• Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.

  2023cites this paper
• Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease

  2023cites this paper
• Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.

  2023cites this paper
• High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies

  2023cites this paper
• Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

  2023cites this paper
• Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches

  2022cites this paper
• Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

  2022cites this paper
• iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis.

  2022cites this paper
• Cellular and molecular diversity in rheumatic autoimmune diseases.

  2022cites this paper
• Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

  2022cites this paper
• Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

  2022cites this paper
• Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.

  2022cites this paper
• Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease

  2022cites this paper
• Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis

  2022cites this paper
• Predicting the Progression of Very Early Systemic Sclerosis: Current Insights

  2022cites this paper
• Development of a scoring system with multidimensional markers for fibrosing interstitial lung disease

  2022cites this paper
• Therapeutic potential for P2Y2 receptor antagonism

  2022cites this paper
• Connective tissue disease-related interstitial lung disease is alleviated by tripterine through inhibition of the PI3K/Akt, apoptosis, and TNF-α signalling pathways

  2022cites this paper
• Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease

  2022cites this paper
• Systemic sclerosis.

  2022cites this paper
• Updated Treatment Modalities of Systemic Sclerosis: Review Article

  2022cites this paper
• Assessment of disease outcome measures in systemic sclerosis

  2022cites this paper
• Interstitial pneumonia with autoimmune features

  2022cites this paper
• Lung involvement in systemic sclerosis

  2022cites this paper
• A case of generalized morphea profunda following SARS-CoV-2 infection

  2022cites this paper
• The Roles of Noncoding RNAs in Systemic Sclerosis

  2022influential citation
• Treatment approach to connective tissue disease-associated interstitial lung disease.

  2022cites this paper
• Dysregulated Cell–Cell Communication Characterizes Pulmonary Fibrosis

  2022cites this paper
• SSc biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

  2021cites this paper
• Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction

  2021cites this paper
• Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis

  2021cites this paper
• The Case of a Patient with Limited Systemic Sclerosis and Interstitial Lung Disease Overlapping with Systemic Lupus Erythematosus

  2021cites this paper
• Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins

  2021cites this paper
• Systemic Sclerosis and Pulmonary Disease.

  2021cites this paper
• Spectrum of Interstitial Lung Disease in Rheumatic Diseases

  2021cites this paper
• Association of Serum IL 6 with Different Clinical Presentations of Systemic Sclerosis Patients: A Case-Control Study

  2021influential citation
• Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study

  2021cites this paper
• Treatment Options for Interstitial Lung disease associated with Connective Tissue Disease

  2021cites this paper
• Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

  2021cites this paper
• Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease

  2021cites this paper
• Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial.

  2021cites this paper
• Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion

  2021cites this paper
• Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response

  2021cites this paper
• CD19 + CD21lo/neg cells are increased in systemic sclerosis-associated interstitial lung disease

  2021cites this paper
• Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience

  2021influential citation
• Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis

  2021cites this paper
• Novel role of long non-coding RNAs in autoimmune cutaneous disease.

  2021cites this paper
• Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases

  2021cites this paper
• Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease

  2021cites this paper
• Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations

  2021cites this paper
• Systemic sclerosis‐associated interstitial lung disease treated with tocilizumab

  2021cites this paper
• Pulmonary disease as a risk factor for transfusion-related acute lung injury

  2021cites this paper
• Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis.

  2021cites this paper
• Association of Circulating Vascular Endothelial Growth Factor Levels With Autoimmune Diseases: A Systematic Review and Meta-Analysis

  2021cites this paper
• An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years

  2021cites this paper
• Association of Serum Biomarkers With Pulmonary Involvement of Rheumatoid Arthritis Interstitial Lung Disease: From KORAIL Cohort Baseline Data

  2021influential citation